Pancreatitis or inflammation of the pancreas comes in both acute and chronic forms and has long been appreciated as a risk factor for developing pancreatic cancer. While common and in […]
Daraxonrasib, a game changer for pancreatic cancer patients
The wait is over. On Sunday May 31st 2026, Brian M Wolpin MD, MPH, the Director of the Hale Family Center for Pancreatic Cancer Research at Dana Farber Cancer Institute, […]
Innovative Glycoengineering Strategy Could Reveal New Biomarkers for Pancreatic Cancer
While the 5-year survival rate for pancreatic cancer has increased over the last decade to 13%, it continues to be one of the toughest cancers to diagnose and treat. One […]
FDA Expands Access to Daraxonrasib: What Patients Need to Know
The FDA has granted permission for Revolution Medicines to provide access to its investigational RAS inhibitor, daraxonrasib, through an Expanded Access Program (EAP) for certain patients with metastatic pancreatic ductal […]
The Promise of Personalized Pancreatic Cancer Vaccines
From April 17-22, 2026, the American Association for Cancer Research (AACR) held their annual meeting in San Diego, CA. The AACR Annual Meeting brings together clinicians, researchers, and health-care professionals […]
Researchers Identify Tumor-Suppressing Mechanism in Healthy Pancreas
The American Association for Cancer Research (AACR) held their annual meeting in San Diego, CA from April 17-22, 2026. The AACR Annual Meeting gathers cancer researchers from around the world […]